1. Takatoku M, Uchiyama T, Okamoto S, et al. Retrospective nationwide survey of Japanese patients with
transfusion-dependent MDS and aplastic anemia highlights the negative impact of iron overload on morbidity/
mortality. Eur J Haematol. 2007;78(6):487–494. doi:10.1111/j.1600-0609.2007.00842.x.
2. Kohgo Y, Urabe A, Kilinç Y, et al. Deferasirox decreases liver iron concentration in iron-overloaded
patients with myelodysplastic syndromes, aplastic anemia and other rare anemias. Acta Haematol.
2015;134(4):233–242. doi:10.1159/000381893.
3. Ganz T, Nemeth E. Hepcidin and iron homeostasis. Biochim Biophys Acta. 2012;1823(9):1434–1443.
doi:10.1016/j.bbamcr.2012.01.014.
4. Bridle KR, Frazer DM, Wilkins SJ, et al. Disrupted hepcidin regulation in HFE-associated haemochromatosis
and the liver as a regulator of body iron homoeostasis. Lancet. 2003;361(9358):669–673. doi:10.1016/
S0140-6736(03)12602-5.
5. Camaschella C, Nai A. Ineffective erythropoiesis and regulation of iron status in iron loading anaemias. Br
J Haematol. 2016;172(4):512–523. doi:10.1111/bjh.13820.
6. Hattori A, Miyajima H, Tomosugi N, et al. Clinicopathological study of Japanese patients with genetic iron
overload syndromes. Pathol Int. 2012;62(9):612–618. doi:10.1111/j.1440-1827.2012.02848.x.
7. Kawabata H. The mechanisms of systemic iron homeostasis and etiology, diagnosis, and treatment of
hereditary hemochromatosis. Int J Hematol. 2018;107(1):31–43. doi:10.1007/s12185-017-2365-3.
8. Kaneko Y, Miyajima H, Piperno A, et al. Measurement of serum hepcidin-25 levels as a potential test for
diagnosing hemochromatosis and related disorders. J Gastroenterol. 2010;45(11):1163–1171. doi:10.1007/
s00535-010-0259-8.
9. Kikuchi S, Kobune M, Iyama S, et al. Improvement of iron-mediated oxidative DNA damage in patients
with transfusion-dependent myelodysplastic syndrome by treatment with deferasirox. Free Radic Biol Med.
2012;53(4):643–648. doi:10.1016/j.freeradbiomed.2012.06.006.
...
論文の公開元へ
